Proven science. New technology

Our current therapeutic focus is on the clinical development of the novel drug, lotilaner, for the first time in human medicine. If approved, our candidate, TP-03, would be the first FDA-approved treatment for Demodex blepharitis.

Our Pipeline

We’re looking for new ways to apply proven science to solve large problems. Our pipeline of wholly owned candidates addresses a number of diseases with high unmet needs across a range of therapeutic categories including eye care, dermatology, and infectious disease prevention.

Candidate
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Demodex blepharitis
TP-03
Meibomian gland disease
(MGD)
Demodex blepharitis
(preservative-free)
Preservative-free formulation to be tested after NDA submission
Demodex blepharitis
and MGD in China
(partnership with LianBio)
TP-04
Rosacea
Lyme disease
TP-05
Malaria
TP-03
TP-04
TP-05
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
Demodex blepharitis
Meibomian gland disease (MGD)
Demodex blepharitis (preservative-free)
Preservative-free formulation to be tested after NDA submission
Demodex blepharitis and MGD in China
(partnership with LianBio)
Rosacea
Lyme disease
Malaria
Candidate
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Demodex blepharitis
TP-03
Meibomian gland disease
(MGD)
Demodex blepharitis
(preservative-free)
Preservative-free formulation to be tested after NDA submission
Demodex blepharitis
and MGD in China
(partnership with LianBio)
TP-04
Rosacea
Lyme disease
TP-05
Malaria

Setting a target on unmet needs

Beyond Demodex blepharitis, a number of parasite-mediated diseases have high clinical unmet needs. By applying our unique approach to research and development, we’re investigating solutions to target MGD, rosacea, Lyme disease, and malaria.

TP-04 for the potential treatment of rosacea

Rosacea is a chronic skin disease characterized by facial redness, inflammatory lesions, burning and stinging, which can flare up in response to certain triggers such as sun exposure or emotional stress. According to the U.S. National Rosacea Society, approximately 16 million people in the United States are affected by rosacea and a study estimates rosacea prevalence can represent up to 5.4% of the global population. We intend to develop TP-04 as a topical formulation.

TP-05 for potential Lyme disease prophylaxis and community malaria reduction

Lyme disease is the most common vector-borne disease in the United States, caused by infection of Borrelia bacteria following bite by a tick vector. Estimates of annual cases of Lyme disease in the United States range from approximately 300,000 to 400,000. Malaria is one of the world’s highest unmet public health needs, with approximately 228 million cases and more than 400,000 deaths caused by malaria worldwide. We are developing TP-05 as an oral formulation that is designed as a prophylactic drug against Lyme disease to eradicate the tick before it can transmit the Borrelia bacteria. Further TP-05 also has the potential to cause the death of mosquitos that transmit malaria.

Contact Tarsus

Please reach out to us using the form below.

General Information
Investor Relations
Careers
Opt in to be the first to receive the latest Tarsus news
Contact Tarsus

Thank you for getting in touch! Someone from our team will respond shortly.